Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis.
Olgun Eliçin(University of Bern), Daniel M. Aebersold(University of Bern), Pınar Ambarcıoğlu, Pirus Ghadjar(Humboldt-Universität zu Berlin), Ludwig Plaßwilm(University of St. Gallen), Daniel Rauch(Washington University in St. Louis), M. Schmücking(University of Bern), Roland Giger(University of Bern), Jens O. Brömme(University of Bern), Andreas Geretschläger(University of Bern)
PubMed
May 16, 2016
Cited by 5
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
|Annals of Oncology|2016|140